At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,671 enrolled
Drug / intervention
Sulopenem-Etzadroxil/Probenecid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Phase 3 Randomized Multi-center Double-blind Study of Efficacy Tolerability & Safety of Oral Sulopenem-etzadroxil/Probenecid vs Ciprofloxacin for Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women
In Brief
A Phase 3 clinical trial evaluating Sulopenem-Etzadroxil/Probenecid and Ciprofloxacin for Uncomplicated Urinary Tract Infections. Completed, enrolled 1,671 participants across 60 sites.
Detailed Summary
This is a prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability, and safety of oral sulopenem-etzadroxil/probenecid versus oral ciprofloxacin for treatment of uncomplicated urinary tract infection (uUTI) in adult women
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUncomplicated Urinary Tract Infections
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartAug 2018
Primary CompletionJan 2020
Study CompletionJan 2020
TodayJul 2026
First PostedNov 28, 2017
Enrollment StartAug 1, 2018
Primary CompletionJan 16, 2020
Study CompletionJan 20, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.6 years ago
Interventions
Sulopenem-Etzadroxil/Probeneciddrug
Treatment of uncomplicated urinary tract infection
Ciprofloxacindrug
Treatment of uncomplicated urinary tract infection